Oncology Clinical Trials in Tucson, AZ
As of June 2026, 116 paid clinical trials are recruiting for Oncology in Tucson, Arizona. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
116 clinical trials for Oncology
·Clear filters·↓ Download CSVProphylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
Social Optimization Study
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
About research studies in Tucson
Tucson has approximately 520 recruiting research studies across a wide range of therapeutic areas. Arizona is home to Mayo Clinic Arizona, Banner - University Medical Center, and TGen (Translational Genomics Research Institute), with active research in oncology and precision medicine.
Top Research Study Locations in Tucson
Researchers run research studies in Tucson, AZ at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| University of Arizona | Amblyopia, Breast Cancer, Aging | 82 |
| Banner University Medical Center - Tucson | Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Diffuse Large B-Cell Lymphoma | 61 |
| University of Arizona Cancer Center-North Campus | Acute Myeloid Leukemia, Stage IVB Prostate Cancer AJCC v8, Recurrent Diffuse Large B-Cell Lymphoma | 47 |
| University of Arizona Cancer Center | Breast Cancer, Advanced Solid Tumor, Hepatocellular Carcinoma | 27 |
| The University of Arizona Cancer Center | Advanced Solid Tumor, Breast Cancer, Metastatic Solid Tumor | 13 |
| University of Arizona Cancer Center-Orange Grove Campus | Stage IVB Prostate Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | 11 |
| Del Sol Research Management, LLC | Chronic Idiopathic Constipation (CIC), Contraception, Influenza | 9 |
| Banner University Medical Center | Arteriovenous Fistula, Atrial Fibrillation, Catheter Complications | 8 |
| Pima Heart and Vascular | Heart Failure, Atrial Fibrillation, Deep Venous Thrombosis | 8 |
| Tucson Medical Center | Aortic Valve Stenosis, Mitral Regurgitation, Tricuspid Regurgitation | 8 |
| GSK Investigational Site | Chickenpox, Breast Neoplasms, Colonic Neoplasms | 7 |
| The University of Arizona Cancer Center - North Campus | Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung, Acute Myeloid Leukemia Refractory | 7 |
| Center for Neurosciences | Focal Epilepsy, Glioblastoma (GBM), Intermediate Risk Non-Muscle Invasive Bladder Cancer | 6 |
| Arizona Liver Health - Tucson | Liver Fibrosis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis | 5 |
| Arizona Oncology Associates | Breast Cancer, Cancer, HER2-negative Breast Cancer | 5 |
| Arizona Urology Specialists | Prostate Cancer, Benign Prostatic Hyperplasia (BPH), Bladder Pain Syndrome | 5 |
| Del Sol Research Management | Major Depressive Disorder, Familial Adenomatous Polyposis, Lower Urinary Tract Symptoms (LUTS) | 5 |
| Noble Clinical Research | Bipolar Depression, Bipolar Disorder, Bipolar I Disorder | 5 |
| Arizona Clinical Trials | Obesity or Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 4 |
| Pima Heart & Vascular | Atrial Fibrillation, Coronary Artery Disease, High-Risk Percutaneous Coronary Intervention | 4 |
| Tucson Cystic Fibrosis Center | Cystic Fibrosis, Cystic Fibrosis Lung, Cystic Fibrosis Pulmonary Exacerbation | 4 |
| University of Arizona Cancer Center - Prevention Research Clinic | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Breast Atypical Ductal Hyperplasia | 4 |
| University of Arizona College of Medicine | Cancer, Diabetes, Diabetic Foot | 4 |
| Tucson Clinical Research Institute | Diabetes Mellitus, Type 2, Obesity, Overweight | 4 |
| Adobe Clinical Research, LLC | Liver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis, Metabolic Dysfunction Associated Steatohepatitis (MASH) | 3 |
Active & Upcoming Studies in Tucson (2026)
Recruiting trials in Tucson grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (181 active studies)
- A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer · Phase 1 · University of Wisconsin, Madison
- GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer · EARLY_Phase 1 · University of Arizona
Neurology & pain (34 active studies)
- Hypknowledge Nationwide Sleep Extension · University of Arizona
- Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) · Phase 3 · Ambros Therapeutics, Inc.
Cardiovascular (34 active studies)
- Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) · Phase 2 · Stanford University
- A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation · Biosense Webster, Inc.
Diabetes & metabolic (30 active studies)
Mental health & behavior (9 active studies)
- Lumateperone for Late-Life Depression · Phase 3 · Eric Lenze
- Service Dogs and Prolonged Exposure Therapy for Military-Connected PTSD · University of Arizona
Vaccines (3 active studies)
- A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza · Phase 3 · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC). · Phase 2, Phase 3 · HealthBio, Inc.
Eye & vision (3 active studies)
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration · Phase 3 · 4D Molecular Therapeutics
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy · Phase 3 · Regeneron Pharmaceuticals
Pediatric (2 active studies)
- CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) · Phase 1, Phase 2 · COUR Pharmaceutical Development Company, Inc.
- A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy · Phase 2 · Eisai Inc.
HIV / STI (1 active study)
- Wellness Intervention for Smoking and HIV · University of Arizona
Common conditions studied in Tucson
- Breast Cancer (14 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Acute Myeloid Leukemia (8 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Breast Neoplasms (8 active studies). Recruiting Breast Neoplasms studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Obesity (8 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Heart Failure (7 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Overweight (7 active studies). Recruiting Overweight studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Tucson
- University of Arizona
- AstraZeneca
- National Cancer Institute (NCI)
- Eli Lilly and Company
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Arizona are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Arizona research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Tucson. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Tucson
Hipa.ai aggregates every recruiting study in Tucson from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Tucson?
There are approximately 520 recruiting clinical trials in Tucson, Arizona listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Tucson pay participants?
Most recruiting trials in Tucson compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Tucson?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Tucson?
The most common conditions under active study in Tucson include Breast Cancer (14), Acute Myeloid Leukemia (8), Breast Neoplasms (8), Obesity (8), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Tucson?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Tucson on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Tucson?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Tucson?
Recruiting research sites in Tucson include University of Arizona, Banner University Medical Center - Tucson, University of Arizona Cancer Center-North Campus, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Tucson right now?
The largest active categories in Tucson are Cancer & tumors (181), Neurology & pain (34), Cardiovascular (34). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.